Company / Operating Cash Flow per Share
Corvus Pharmaceuticals, Inc. Operating Cash Flow per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.42
FY2024
5-year range
-$1.18 / -$0.42
FY2020-FY2024
Trend
+16.4%
vs FY2023
Sector context
#91 of 210
Health Care
What the data says
At $-0.42, Corvus Pharmaceuticals, Inc.'s operating cash flow per share ranks #91 of 210 in the Health Care sector. Operating Cash Flow per Share has increased for 7 consecutive years, from $-2.26 in FY2017 to $-0.42 in FY2024.
Based on SEC 10-K filings.
-0.42 in FY2024.
Improved from $-0.58 to $-0.42 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#91 of 210 in Health CareTop 43% of 210This company -$0.42 Sector average $5.30
▼
-107.9% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s operating cash flow per share has grown for 7 consecutive years.
- In FY2024, operating cash flow per share increased 16.4% year-over-year.
- Ranks #91 out of 210 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.42 | +16.4% |
| FY2023 | -$0.50 | +14.1% |
| FY2022 | -$0.58 | +33.8% |
| FY2021 | -$0.88 | +25.6% |
| FY2020 | -$1.18 | +7.2% |
| FY2019 | -$1.27 | +14.7% |
| FY2018 | -$1.49 | +33.9% |
| FY2017 | -$2.26 | -24.9% |
| FY2016 | -$1.81 | +94.0% |
| FY2015 | -$30.32 | -5277.5% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026